Health outcomes 3 months and 6 months after molnupiravir treatment for COVID-19 for people at higher risk in the community (PANORAMIC): a randomised controlled trial

作者：Victoria Harris, Jane Holmes, Oghenekome A. Gbinigie-Thompson, Najib M. Rahman, Duncan Richards, Gail Hayward, Jienchi Dorward, David M. Lowe, Joseph F. Standing, Judith Breuer, Saye Khoo, Stavros Petrou, Kerenza Hood, Haroon Ahmed, Andrew Carson‐Stevens, Jonathan S. Nguyen‐Van‐Tam, Mihir Patel, Benjamin R. Saville, Nick Francis, Nicholas Thomas, Philip Evans, Melissa Dobson, May Ee Png, Mark Lown, Oliver van Hecke, Bhautesh Jani, Nigel Hart, Daniel Butler, Lucy Cureton, Meena Patil, Monique Andersson, Maria Coates, Clare Bateman, Jennifer Davies, Ivy Raymundo-Wood, Andrew Ustianowski, Ly‐Mee Yu, Richard Hobbs, Paul Little, Christopher Butler, Areej Moftah, Anna Goodman, Rob Halifax, Chris Turnbull, Anand Sundaralingam, Akosua Agyeman, Divya Shah, Julianne Brown, Chris Thalasselis, Maximillian N J Woodall, Francis Yongblah, Aleksandra Howell, Kavil Patel, Iqbal Hussain, Ruth Penfold, Simon Hutchinson, Satveer Poonian, Marie Imlach, Olajide Popoola, Greg Irving, Alexander Pora, Nicholas Jacobsen, Vibhore Prasad, James Kennard, Rishabh Prasad, Umar Khan, Omair Razzaq, Kyle Knox, Scot Richardson, Christopher Krasucki, Simon Royal, Tom Law, Afsana Safa, Rem Lee, Satash Sehdev, Nicola Lester, Tamsin Sevenoaks, David Lewis, Aadil Sheikh, James Lunn, Vanessa Short, Claire Mackintosh, Baljinder Singh Sidhu, Mehul Mathukia, Ivor Singh, Patrick Moore, Yusuf Soni, Seb Morton, Pete Wilson, Daniel Murphy, David Wingfield, Rhiannon Nally, Michael Wong, Chinonso Ndukauba, Nick Wooding, Olufunto Ogundapo, Sharon Woods, Henry Okeke, Joanna Yong, Tanveer Ahmed, Damien Allcock, George Atherton, Adrian Beltran-Martinez, Oluseye Emmanuel Benedict, Nigel Bird, Laura Brennan, Gerard Burns, Mike Butler, Daniel Butler, Andrew Carson-Stevens, Zelda Cheng, Ruth Danson, Nigel De Kare-Silver, Devesh Dhasmana, Jon Dickson, Serge Engamba, Stacey Fisher, Robin Fox, Eve Frost, Richard Gaunt, Sarit Ghosh, Ishtiaq Gilkar, Anna Goodman, Steve Granier, Alice Packham, Sarah Dowsell, Radhika Gulati, Amit Patel · 发表于：The Lancet Infectious Diseases · 年份：2024 · DOI：10.1016/s1473-3099(24)00431-6 · 被引用次数：19 · 研究领域：Long-Term Effects of COVID-19、SARS-CoV-2 and COVID-19 Research、COVID-19 Clinical Research Studies

BACKGROUND: No randomised controlled trials have yet reported on the effectiveness of molnupiravir on longer term outcomes for COVID-19. The PANORAMIC trial found molnupiravir reduced time to recovery in acute COVID-19 over 28 days. We aimed to report the effect of molnupiravir treatment for COVID-19 on wellbeing, severe and persistent symptoms, new infections, health care and social service use, medication use, and time off work at 3 months and 6 months post-randomisation. METHODS: This study is a follow-up to the main analysis, which was based on the first 28 days of follow-up and has been previously reported. For this multicentre, primary care, open-label, multi-arm, prospective randomised controlled trial conducted in the UK, participants were eligible if aged at least 50 years, or at least 18 years with a comorbidity, and unwell 5 days or less with confirmed COVID-19 in the community. Participants were randomly assigned to the usual care group or molnupiravir group plus usual care (800 mg twice a day for 5 days), which was stratified by age (<50 years or ≥50 years) and vaccination status (at least one dose: yes or no). The primary outcome was hospitalisation or death (or both) at 28 days; all longer term outcomes were considered to be secondary outcomes and included self-reported ratings of wellness (on a scale of 0-10), experiencing any symptom (fever, cough, shortness of breath, fatigue, muscle ache, nausea and vomiting, diarrhoea, loss of smell or taste, headache, diz...